프레가발린 세계 시장 규모는 2023년에 19억 달러로 평가되었으며, 2024년 19억 7,000만 달러에서 2032년에는 26억 6,000만 달러로 성장하여 예측 기간(2025-2032년) 동안 CAGR 3.8%로 성장할 전망입니다.
세계 프레가발린 시장은 간질, 신경병성 통증, 섬유근육통, 불안 등 신경질환의 유병률 증가, 특히 25-60세 사이의 성인에서 두드러진 성장세를 보이고 있으며, 세계보건기구(WHO)에 따르면 전 세계적으로 5,000만 명 이상의 간질 환자가 있으며, 적절한 치료를 받으면 70%가 발작 없는 삶을 살 수 있다고 합니다. 살 수 있는 가능성이 있습니다. 성인은 이러한 만성질환에 대한 감수성이 높기 때문에 여전히 주요 소비자 그룹입니다. 또한, 저소득층 및 치료 접근성이 낮은 지역에서의 접근성을 개선하기 위한 주요 기업들의 전략적 노력도 시장 확대에 기여하고 있습니다. 저소득 국가에서는 약 75-90%의 간질 환자가 충분한 치료를 받지 못하고 있으며, 이러한 미충족 수요를 충족시키는 것이 큰 성장 기회로 작용하고 있습니다. 대상 인구의 증가와 전 세계 질병 부담의 증가는 프레가발린 치료제에 대한 시장 수요를 지속적으로 촉진하고 있습니다.
Global Pregabalin Market size was valued at USD 1.9 billion in 2023 and is poised to grow from USD 1.97 billion in 2024 to USD 2.66 billion by 2032, growing at a CAGR of 3.8% during the forecast period (2025-2032).
The global pregabalin market is witnessing significant growth driven by the rising prevalence of neurological conditions such as epilepsy, neuropathic pain, fibromyalgia, and anxiety, especially among adults aged 25 to 60. According to WHO, over 50 million people suffer from epilepsy globally, with up to 70% potentially living seizure-free if properly treated. Adults remain the dominant consumer group due to their higher susceptibility to these chronic disorders. Additionally, strategic initiatives by key players to improve access in low-income and underserved regions are bolstering market expansion. With around 75-90% of epilepsy patients in low-income countries lacking adequate treatment, addressing this unmet need presents a major growth opportunity. The growing target population and increasing global disease burden continue to fuel market demand for pregabalin therapies.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pregabalin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Pregabalin Market Segments Analysis
Global Pregabalin Market is segmented by Forms, Application, Drug Class, Distribution Channel, End User and region. Based on Forms, the market is segmented into Oral Capsule, Oral Solution, Oral Tablet and Extended Release. Based on Application, the market is segmented into Epilepsy, Neuropathic Pain, Anxiety Disorder and Others. Based on Drug Class, the market is segmented into Fibromyalgia Agents, Anticonvulsants and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Pregabalin Market
The global pregabalin market is being significantly driven by the rising incidence of neuropathic pain and generalized anxiety disorders. Healthcare professionals in both developed and emerging markets are increasingly turning to pregabalin due to its dual therapeutic benefits for managing chronic pain as well as alleviating anxiety symptoms. In 2024, treatment guidelines in countries like Canada and Australia were updated to recognize pregabalin as a first-line option, further enhancing its adoption in both neurological and psychiatric treatments. This growing acceptance among medical practitioners is contributing to an upsurge in pregabalin's utilization worldwide, thereby expanding its market footprint.
Restraints in the Global Pregabalin Market
The global pregabalin market faces significant constraints primarily due to its classification as a controlled substance in many countries, which hampers its market growth. Regulatory restrictions, particularly concerning prescribing practices, stem from concerns about the drug's potential for abuse and dependence. This has resulted in a slower adoption rate within various healthcare settings, including general care units and outpatient services. For instance, in 2024, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) reaffirmed pregabalin's status as a Schedule 3 medication, which imposes stricter prescription controls and additional record-keeping requirements, further deterring its use among outpatients and primary care providers.
Market Trends of the Global Pregabalin Market
The global pregabalin market is witnessing a robust upward trend, driven by the rising demand for effective neuropathic pain relief solutions. As chronic pain conditions, particularly among aging populations in North America and Europe, become more prevalent, pregabalin, notably branded as Lyrica, has emerged as a go-to therapeutic option for managing ailments such as diabetic neuropathy and post-herpetic neuralgia. To cater to this increasing demand, pharmaceutical companies are innovating by introducing specialized dosage and long-acting formulations. Notably, Pfizer has enhanced its Lyrica CR line with a new formulation specifically designed for geriatric patients, addressing crucial issues of tolerability and compliance, further propelling market growth.